Objectives: 

To assess 1-week and 1-month efficacy of Systane iLux thermal pulsation treatment for meibomian gland dysfunction (MGD).

Methods: 

This prospective, nonrandomized, open-label, multicenter study enrolled 30 adult patients (60 eyes) who had a Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire score greater than 6 and total meibomian gland secretion (MGS) score equal to or less than 12 in each eye. All participants received thermal pulsation treatment bilaterally. Primary efficacy measures included MGS score (sum of grades for 15 glands graded on a scale of 0–3; 0 [no secretion], 1 [inspissated], 2 [cloudy], and 3 [clear liquid]) and tear breakup time (TBUT). Secondary efficacy measures were SPEED and Ocular Surface Disease Index (OSDI) scores.

Results: 

The mean age of patients was 52.9±11.9 years. After 1 week, the mean MGS score improved significantly from 4.1±3.1 to 15.8±7.1 (right eye, OD) and 3.7±3.1 to 16.7±7.6 (left eye, OS); mean TBUT improved significantly from 4.9±4.1 to 8.4±3.6 (OD) and 5.2±4.2 to 8.9±3.9 (OS); and mean SPEED and OSDI scores improved significantly from 16.1±5.3 to 7.2±6.1 and 45.2±21.3 to 19.0±16.8, respectively (all P<0.001). After 1 month, the mean MGS score improved to 18.3±8.2 (OD) and 18.6±7.3 (OS); mean TBUT improved to 9.7±3.8 (OD) and 9.6±3.5 (OS); and mean SPEED and OSDI scores improved to 7.0±5.6 and 16.7±14.5, respectively (all P<0.001). No adverse events were reported.

Conclusions: 

Systane iLux thermal pulsation treatment for MGD resulted in a statistically significant increase in meibomian gland secretion, improvement in tear film stability, and reduction in dry eye symptoms as early as both 1 week and 1 month.

中文翻译：

---

Systane iLux 热脉动系统治疗 1 周和 1 个月后睑板腺功能障碍的疗效：一项前瞻性研究

目标： 

评估Systane iLux热脉动治疗睑板腺功能障碍 (MGD) 的 1 周和 1 个月疗效。

方法： 

这项前瞻性、非随机、开放标签、多中心研究招募了 30 名成年患者（60 只眼），他们的眼干症标准患者评估 (SPEED) 问卷评分大于 6 且睑板腺总分泌 (MGS) 评分等于或小于每只眼睛 12 个。所有参与者都接受了双侧热脉动治疗。主要疗效指标包括 MGS 评分（15 个腺体的评分总和，评分为 0-3；0 [无分泌]、1 [浓缩]、2 [混浊]和 3 [透明液体]）和泪液破裂时间（待定）。次要疗效指标是速度和眼表疾病指数 (OSDI) 评分。

结果： 

患者的平均年龄为 52.9±11.9 岁。1 周后，平均 MGS 评分从 4.1±3.1 显着提高至 15.8±7.1（右眼，OD）和 3.7±3.1 至 16.7±7.6（左眼，OS）；平均 TBUT 从 4.9±4.1 显着改善至 8.4±3.6 (OD) 和 5.2±4.2 至 8.9±3.9 (OS)；平均 SPEED 和 OSDI 得分分别从 16.1±5.3 显着提高至 7.2±6.1 和 45.2±21.3 至 19.0±16.8（均P <0.001）。1个月后，平均MGS评分提高到18.3±8.2（OD）和18.6±7.3（OS）；平均 TBUT 提高到 9.7±3.8 (OD) 和 9.6±3.5 (OS)；平均 SPEED 和 OSDI 得分分别提高到 7.0±5.6 和 16.7±14.5（均P <0.001）。未报告任何不良事件。

结论： 

MGD 的Systane iLux热脉动治疗早在 1 周和 1 个月就导致睑板腺分泌的统计学显着增加、泪膜稳定性的改善以及干眼症症状的减少。